Some folks seem to wonder whether a hyperacute phase (as I predict) will follow the current, more 'chronic' course of the C-19 pandemic or if the increase in mortality will instead be driven by a gradual rise in excess deaths directly or indirectly caused by the insane C-19 vaccination program.
While I am not a prophet, I want to emphasize that the current 'chronic' phase is ‘practically’ unsustainable for the virus. Suppressing the acute course of a virus that naturally causes an acute, self-limiting infection severely hampers its ability to proliferate and spread effectively.
This unsustainable situation can only conclude in one of two ways: Either the virus's spread is halted entirely (hooray!), or a randomly emerging mutant is naturally selected that allows the virus to spread more efficiently, even if it requires the virus to systemically disseminate within the body rather than transmit from one host entry portal to another.
Given the current, prolific emergence of new variants—and their combinations—in a myriad of highly C-19 vaccinated countries, I find it inconceivable that such a 'virulent' phenotype will not emerge and undergo natural selection in the very near future. Due to the high immune pressure on the virus's chances of survival, this will inevitably lead to a hyperacute phase causing a huge wave of severe disease enhancement. Only after this can balance be restored, and we will again deal with an acute, self-limiting course of this viral infection on the backdrop of herd immunity. That a hyperacute phase must precede the end of this immune escape pandemic is bad news, which is why I continue to warn that society in highly C-19 vaccinated countries will be caught off guard (which would not be the case if the 'chronic' course continued).
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
.svg){kind=small}
